Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection

Transplant Immunology

Volumn 22, Issue 1-2, 2009, Pages 99-104

  Christmas, Stephen E ^a   Halliday, Deborah ^a   Lawton, Nichola ^a   Wang, Haiyi ^a   Abdalla, Ibrahim ^a   Masters, James ^a   Hassan, Rebecca L ^a   Hart, Ian J ^b   Khan, Naeem ^a   Smith, Jane ^b   Hammad, Abdul ^b   Bakran, Ali ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cytomegalovirus; HLA tetramers; Kidney transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; TETRAMER; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHOPROTEINS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; YOUNG ADULT;

EID: 70449536483     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2009.07.003     Document Type: Article

References (46)

1. Quinnan G.V.J., Burns W.H., Kirmani N., Rook A.H., Manischewitz J., Jackson L., et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis 6 (1984) 156-163
2. Moss P., and Khan N. CD8+ T-cell immunity to cytomegalovirus. Hum Immunol 65 (2004) 456-464
3. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp 65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 (1996) 7569-7579
4. Fishman J.A., Emery V., Freeman R., Pascual M., Rostaing L., Schlitt H.J., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21 (2007) 149-158
5. Pescovitz M.D. A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus. Kidney Int 72 (2007) 912-913
6. Cappel R., Hestermans O., Toussaint C., Vereerstraeten P., van Beers D., de Braekeleer J., et al. Cytomegalovirus infection and graft survival in renal graft recipients. Arch Virol 56 (1978) 149-156
7. Pouteil-Noble C., Ecochard R., Landrivon G., Donia-Maged A., Tardy J.C., Bosshard S., et al. Cytomegalovirus infection-an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 55 (1993) 851-857
8. Toupance O., Bouedjoro-Camus M.C., Carquin J., Novella J.L., Lavaud S., Wynckel A., et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int 13 (2000) 413-419
9. Sagedal S., Nordal K.P., Hartmann A., Midtvedt K., Foss A., Asberg A., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2 (2002) 850-856
10. McLaughlin K., Sandhu S., Wu C., Muirhead N., Hollomby D., and Jevnikar A. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. Nephrol Dial Transplant 20 (2005) 176-180
11. Hartmann A., Sagedal S., and Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 82 2 Suppl (2006) S15-S17
12. Reischig T., Jindra P., Svecová M., Kormunda S., Opatrný K.J., and Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 36 (2006) 146-151
13. Li L., Chaudhuri A., Weintraub L.A., Hsieh F., Shah S., Alexander S., et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 11 (2007) 187-195
14. Helanterä I., Koskinen P., Finne P., Loginov R., Kyllönen L., Salmela K., et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transplant Int 19 (2006) 893-900
15. Markovic-Lipkovski J., Müller C.A., Engler-Blum G., Strutz F., Kühn W., Risler T., et al. Human cytomegalovirus in rejected kidney grafts; detection by polymerase chain reaction. Nephrol Dial Transplant 7 (1992) 865-870
16. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
17. Gratama J.W., and Kern F. Flow cytometric enumeration of antigen-specific T lymphocytes. Cytometry A 58 (2004) 79-86
18. Engstrand M., Tournay C., Peyrat M.A., Eriksson B.M., Wadstrom J., Wirgart B.Z., et al. Characterization of CMVpp 65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 69 (2000) 2243-2250
19. Boeckh M., Huang M., Ferrenberg J., Stevens-Ayers T., Stensland L., Nichols W.G., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42 (2004) 1142-1148
20. Tong C.Y., Cuevas L., Williams H., and Bakran A. Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients. J Clin Microbiol 36 (1998) 2681-2685
21. Rubin R.H., Kemmerly S.A., Conti D., Doran M., Murray B.M., Neylan J.F., et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2 (2000) 112-117
22. La Rosa C., Limaye A.P., Krishnan A., Longmate J., and Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195 (2007) 633-644
23. Hilton R.M., Hargreaves R.E., Sacks S.H., and O'Callaghan C.A. Direct visualisation of cytomegalovirus-specific CD8+ T cells in renal transplant recipients. Transplant Proc 34 (2002) 1171-1173
24. Hoffmann T.W., Halimi J.M., Büchler M., Velge-Roussel F., Goudeau A., Al Najjar A., et al. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 85 (2008) 1406-1411
25. Tan B.H. CMV prophylaxis-to do or not to do, that is the question. Nephrol Dial Transplant 21 (2006) 1757-1761
26. Squifflet J.P., and Legendre C. The economic value of valacyclovir prophylaxis in transplantation. J Infect Dis 186 Suppl1 (2002) S116-S122
27. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340 (1999) 1462-1470
28. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., and Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 8 (2008) 975-983
29. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 16 (2006) 281-287
30. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9 (2009) 1214-1222
31. Cainelli F., and Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship?. Lancet Infect Dis 2 (2002) 539-549
32. Adams A.B., Williams M.A., Jones T.R., Shirasugi N., Durham M.M., Kaech S.M., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111 (2003) 1887-1895
33. Söderberg-Nauclér C., Fish K.N., and Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91 (1997) 119-126
34. von Willebrand E., Pettersson E., Ahonen J., and Häyry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 42 (1986) 364-367
35. Fietze E., Prösch S., Reinke P., Stein J., Döcke W.D., Staffa G., et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 58 (1994) 675-680
36. Sagedal S., Hartmann A., and Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 11 (2005) 518-530
37. Lidehall A.K., Sund F., Lundberg T., Eriksson B.M., Tötterman T.H., and Korsgren O. T cell control of primary and latent cytomegalovirus infections in healthy subjects. J Clin Immunol 25 (2005) 473-481
38. van de Berg P.J., van Stijn A., Ten Berge I.J., and van Lier R.A. A fingerprint left by cytomegalovirus infection in the human T cell compartment. J Clin Virol 41 (2008) 213-217
39. Khan N., Shariff N., Cobbold M., Bruton R., Ainsworth J.A., Sinclair A.J., et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169 (2002) 1984-1992
40. Vescovini R., Biasini C., Fagnoni F.F., Telera A.R., Zanlari L., Pedrazzoni M., et al. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J Immunol 179 (2007) 4283-4291
41. Hadrup S.R., Strindhall J., Køllgaard T., Seremet T., Johansson B., Pawelec G., et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 176 (2006) 2645-2653
42. Koch S., Larbi A., Ozcelik D., Solana R., Gouttefangeas C., Attig S., et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 1114 (2007) 23-35
43. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007) 670-684
44. Engstrand M., Lidehall A.K., Totterman T.H., Herrman B., Eriksson B.M., and Korsgren O. Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp 65 are present but display functional impairment. Clin Exp Immunol 132 (2003) 96-104
45. Mattes F.M., Vargas A., Kopycinski J., Hainsworth E.G., Sweny P., Nebbia G., et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 8 (2008) 990-999
46. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201 (2005) 1031-1036